Zealand Pharma revenue and financials
kr 248.10Change from previous close: −1.19%Absolute change: −kr 3.00
In the fiscal year ended December 2025, Zealand Pharma reported revenue of kr 9.21B (+14,598.86% year over year). Net income was kr 6.46B, a net margin of 70.0%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +14,598.86%
- 2025 vs 2024
- Net margin
- 70.0%
- 2024: -1,720.9%
Financial data
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 6,532 | -931 | -426 | -942 | — |
| Depreciation and amortization | 27.4 | 25.8 | 25.1 | 118 | 40.2 |
| Capital expenditure | -69.1 | -13.1 | -23.7 | -11.7 | — |
| Investing cash flow | -2,249 | -7,307 | -1,094 | 281 | — |
| Financing cash flow | -378 | 8,288 | 907 | 588 | — |
| Share repurchases | -407 | -352 | -41.6 | 0.0 | — |
| Debt issued | 0.0 | 370 | 0.0 | 0.0 | — |
| Debt repaid | — | 0.0 | -526 | -436 | 0.0 |
| Effect of exchange rates | -54.7 | 6.2 | -7.2 | 13.7 | — |
| Net change in cash | 3,905 | 51.2 | -613 | -73.6 | — |
| Free cash flow | 6,463 | -944 | -449 | -954 | — |